Netarsudil
- Generic Name
- Netarsudil
- Brand Names
- Rhopressa, Rocklatan, Rhokiinsa
- Drug Type
- Small Molecule
- Chemical Formula
- C28H27N3O3
- CAS Number
- 1254032-66-0
- Unique Ingredient Identifier
- W6I5QDT7QI
- Background
A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous
As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.
- Indication
Netarsudil is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension .
- Associated Conditions
- Increased Intra Ocular Pressure (IOP)
Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
- Conditions
- Fuchs' Endothelial DystrophyBullous Keratopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Cornea Research Foundation of America
- Target Recruit Count
- 120
- Registration Number
- NCT03248037
- Locations
- 🇺🇸
Price Vision Group, Indianapolis, Indiana, United States
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
- Conditions
- Primary Open Angle Glaucoma or Ocular Hypertension
- Interventions
- Other: Placebo Comparator
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT03233308
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Duke Eye Center, Durham, North Carolina, United States
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- Other: Netarsudil Ophthalmic Solution Vehicle
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02874846
- Locations
- 🇺🇸
Nancy Ramirez, Bedminster, New Jersey, United States
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- Drug: PG324 Ophthalmic Solution 0.02%/0.005%
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 750
- Registration Number
- NCT02674854
- Locations
- 🇺🇸
Aerie Pharmaceuticals, Bedminster, New Jersey, United States
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- Drug: PG324 Ophthalmic Solution 0.02%/0.005%
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 718
- Registration Number
- NCT02558400
- Locations
- 🇺🇸
Aerie Pharmaceuticals, Bedminster, New Jersey, United States
A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02406287
- Locations
- 🇺🇸
Aerie Pharmaceutical, Bedminster, New Jersey, United States
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: PG324 Ophthalmic Solution 0.01%Drug: PG324 Ophthalmic Solution 0.02%
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 298
- Registration Number
- NCT02057575
- Locations
- 🇺🇸
Comprehensive Eye Care, Saint Louis, Missouri, United States
🇺🇸Stacy R. Smith, M.D., Salt Lake City, Utah, United States
🇺🇸Kenneth Sall, M.D., Artesia, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.